Compare 8x8 Inc (EGHT) vs Eli Lilly And Co (LLY) Price & Performance

EGHT trades at $2.15, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21M in 2025 but shows improving trends with revenue growth to $745M and a projected net profit of $5M in 2026. Recent news highlights cost-saving client wins and AI product growth, while analyst consensus is a Buy with a $19.77 price target, suggesting significant upside potential from current levels.

The outlook is cautiously optimistic, with earnings beats and projected profitability offering opportunity, but high debt and thin margins pose risks. Investor sentiment is mixed amid valuation concerns, yet institutional interest and strategic partnerships support a positive long-term view if execution improves.

Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.

Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.